A clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial.
The company has several programs that offer significant partnering opportunities. The proprietary drug discovery platform technology Magellan™ can also provide partnering opportunities for the discovery of novel brain-penetrant small molecules against novel selected targets.
Its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 mts.